3 new drugs to watch this fall 

Are these new gene therapies worth the price?​

By Sumit Dutta, MD, Chief Medical Officer at Optum Rx | Published: October 2022

Welcome to the fall edition of Drugs to Watch.

As the year begins to close, we highlight three essential pipeline drugs with an expected U.S. Food and Drug Administration (FDA) decision.

Two of the three drugs discussed here have an Orphan Drug designation, while the third was granted Priority Review designation. In today's market, we are seeing new orphan drugs more frequently and expect this trend to continue. However, you may be surprised by the price tag.

The drugs in this report include treatments for:

  • Kidney disease
  • Inherited bleeding disorder
  • Eye disease
Don't want to read the full report? Download the brief summary.
Related content

Rare diseases, large costs

The rise in orphan drugs is offering hope

Articles and blogs

4 more psoriasis drugs on the way

Psoriasis costs up 40% in 5 years. Will these drugs help?
Articles and blogs

Reality check: New drugs will cost more

The trend toward complex biologic drugs continues